UroCure

What UroCure does

UroCure was a privately held U.S. medical device company that re-commercialized midurethral sling systems for the surgical treatment of female stress urinary incontinence (SUI). Founded in May 2017 by John Nealon and Dr. David Staskin, the company acquired the foundational sling IP from Endo/AMS — an original Dr. David Staskin patent from the early 2000s — and built a three-product portfolio: the ArcTV (transvaginal, FDA-cleared February 2019), ArcSP (suprapubic), and ArcTO (transobturator), the latter two cleared in September 2022. All three systems share UroCure's core technology: a laser-cut polypropylene sling with an integrated stabilizing suture that holds the mesh shape during placement, tensioning, and sheath removal, preventing deformation and pore collapse.

The company's business model is a direct medical-device hardware sale model, with three distinct handle-needle configurations (bottom-up, top-down, outside-in) to accommodate surgeon technique preference. U.S. distribution was handled exclusively by LiNA Medical USA under a strategic partnership announced in September 2021, with orders routed through LiNA's national sales force. UroCure layered a patient- and feedback-centric model on top of the hardware business: it established the first Quality and Safety Oversight Committee (QSOC) in women's health (March 2019), pioneered the patient device card for sling implants, and built a QR-code plus text-based feedback channel for surgeons — yielding an ongoing, contemporaneous real-world data channel that few competitors in the category match.

UroCure raised $2.8M in Series A funding (2017) and $1.8M in Series B (January 2020), operated with 1-10 employees, and was headquartered at 1856 Corporate Drive, Norcross, GA. The company was acquired by LiNA Medical USA in January 2026, ending its standalone operating posture; its product line continues under LiNA's ownership.

Name

UroCure

Legal name

UroCure

Website

https://urocure.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

1–10 employees

Short description

UroCure is a U.S. medical device company that developed and marketed three FDA-cleared midurethral sling systems (ArcTV, ArcSP, ArcTO) for the surgical treatment of female stress urinary incontinence, distributed exclusively in the U.S. by LiNA Medical USA.

Ownership category

akta.pro rank

Product category

Medical Devices - Urogynecology / Pelvic Floor Surgery

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Continence Care Products (Adult Incontinence Pads/Briefs, Underpads, External Collectors) (HLAHALAH)

akta.pro secondary industries

Patient Lifts, Transfer & Safe Handling Equipment (Hoists, Slings, Transfer Boards) (HLAHAMAE), Reconstructive Urology & Urethral Stricture Care (HLAKAOAH)

Keywords

• Midurethral sling systems
• Female stress urinary incontinence
• Urogynecology medical devices
• Pelvic floor surgery
• Polypropylene sling implants

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

1. Medical Device Sales: UroCure generates revenue through the sale of its midurethral sling systems (ArcTV, ArcSP, ArcTO) for surgical treatment of female stress urinary incontinence. Products are distributed exclusively through LiNA Medical USA partnership.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

UroCure develops, manufactures, and sells FDA-cleared midurethral sling systems (ArcTV, ArcSP, ArcTO) for the surgical treatment of female stress urinary incontinence (SUI). All three product configurations incorporate a proprietary laser-cut polypropylene sling with an integrated stabilizing suture that prevents deformation during placement, and are sold exclusively through a distribution partnership with LiNA Medical USA to hospitals and specialist physicians.

Product overview

UroCure offers a portfolio of three FDA-cleared midurethral sling systems for the surgical treatment of female stress urinary incontinence (SUI): the ArcTV (transvaginal/bottom-up), ArcSP (suprapubic/top-down), and ArcTO (transobturator/outside-in). All three systems incorporate UroCure's patented laser-cut sling with integrated stabilizing suture technology, which helps prevent deformation and pore collapse during surgical placement. The company differentiates itself through a patient-centered business model that includes ongoing physician feedback collection, a Quality and Safety Oversight Committee (QSOC), and industry-first patient device cards. UroCure products are distributed exclusively by LiNA Medical USA.

Differentiator

Problem solved

Functional benefit

Products and services

• ArcTV Transvaginal Sling System Midurethral sling system following trajectory for transvaginal (bottom-up) needle passage, maintaining rigidity and minimizing needle deflection. Incorporates UroCure's laser-cut sling with integrated stabilizing suture. Indicated for female SUI and used by specialist surgeons in hospital operating rooms.
• ArcSP Suprapubic Sling System Midurethral sling system following trajectory for suprapubic (top-down) needle passage, designed to remain palpable and atraumatic during vaginal tunnel passage. Incorporates UroCure's laser-cut sling with integrated stabilizing suture. Indicated for female SUI and used by specialist surgeons in hospital operating rooms.
• ArcTO Transobturator Sling System Midurethral sling system following trajectory for transobturator (outside-in) needle passage, featuring a unique helical needle design enabling single continuous handle rotation during needle passage until the vaginal incision is reached. Incorporates UroCure's laser-cut sling with integrated stabilizing suture. Indicated for female SUI.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• LiNA Medical USAcoreStrategic or Co-development Partner · 12 January 2026LiNA Medical completed acquisition of UroCure in January 2026, integrating UroCure's clinically proven sling technologies into LiNA's women's health and urogynecology portfolio. UroCure had been a long-standing distribution partner, making this a natural progression. LiNA assumes responsibility for manufacturing, commercialization, and ongoing product support.
• LiNA Medical USAcoreChannel Partner/ Reseller/ Distributor · 21 September 2021Strategic sales distribution and product development partnership announced September 2021. LiNA provides U.S. national sales force and distribution capabilities while UroCure contributes its expanding portfolio of sling products dedicated to women's health. The partnership leverages LiNA's focused women's health device solutions with UroCure's unique sling technology capabilities.
• American Urogynecologic Society (AUGS)coreStrategic or Co-development Partner · 1 April 2019Partnering sponsorship with AUGS ACQUIRE Registry to track patient outcomes following ArcTV sling implantation. UroCure committed to enrolling first 500 patients treated with ArcTV sling in the registry. The partnership supports quality patient outcomes and builds transparency and trust among physicians, patients, regulatory agencies, and industry.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Boston Scientific: Acquired the AMS/Endo sling portfolio (the same franchise UroCure's IP originated from) and sells the Obtryx and Lynx midurethral sling systems. Directly comparable as the dominant incumbent in polypropylene sling procedures in U.S. hospitals.
• Ethicon (Johnson & Johnson MedTech): Original pioneer of the TVT retropubic sling (Gynecare TVT) and a long-standing global leader in midurethral slings for SUI. A broad incumbent whose established sling franchise overlaps directly with UroCure's surgical solutions.
• Becton, Dickinson and Company (BD): Diversified medical device major with a urology and women's health portfolio that includes surgical solutions adjacent to sling procedures. A broad incumbent with overlapping hospital call points in urogynecology.

Direct peers

• Coloplast: Sells the Altis single-incision sling and other midurethral sling systems for female SUI. A direct competitor to UroCure's Arc portfolio targeting the same urogynecology and urology surgical call points.
• Caldera Medical: Women's-health focused medical device company selling the Desara and Vertessa midurethral sling systems for stress urinary incontinence. Closely comparable specialty competitor to UroCure with a similar single-therapeutic-area focus.
• Cook Medical: Markets the Stratasis TF and other transobturator sling products for female SUI. A direct peer offering overlapping surgical approaches and targeting the same urogynecology hospital channels.
• Cogentix Medical (now part of Laborie Medical Technologies): Previously sold the Align urethral support system and other sling products for female incontinence; now integrated into Laborie's broader pelvic floor portfolio. Comparable as a competing midurethral sling vendor.

Regional players

• Promedon: Argentina-based pelvic floor manufacturer offering sling systems (e.g., Nazca TC, Ophira) for female SUI. Comparable on product category but primarily serves Latin American and select international markets rather than the U.S.

Emerging players

• Neomedic International: Smaller specialist offering sling and pelvic floor repair meshes for female incontinence. Comparable as a niche emerging player competing for share with limited commercial reach, similar to UroCure's profile.
• AB Solutions (Atlantic Therapeutics / InnovaMatrix and similar SUI device developers): Developers of non-mesh and conservative SUI therapies (e.g., pelvic floor stimulation devices) that represent an emerging alternative treatment pathway to surgical slings. Comparable as an emerging player addressing the same underlying SUI patient population with a different modality.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/urocure-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UroCure